28 February 2019
Dominated by the contract sales detailing services, the Global Pharma Contract Sales Market is estimated to grow at a CAGR of 7.2%% from 2019 to 2029.
Outsourcing is a growing trend in the pharma industry, with contract providers now offering services from the drug discovery stage through to commercialisation, manufacturing and sales.
Both large and small pharma companies are becoming increasingly reliant upon contract service providers, as they look to focus on perceived core competencies in-house, although companies can now outsource almost any task. Significant changes have been made to pharma sales strategies, with many leading companies cutting sales forces. As pharmaceutical companies are restructuring and cutting operational cost, jobs are being cut especially in divisions that can be outsourced.
Leading companies such as CMIC, IQVIA, Marvecs, Oncall, UDG Healthcare and others are investing in the pharma contract sales market.
The lead analyst commented that "With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide. Greater emphasis is being placed on demonstrating cost-effectiveness and comparative effectiveness to current therapies. In targeting doctors and other stakeholders, including payers, sales reps must become more knowledgeable on health economic data for new therapies, as well as offering benefits for the patient, such as adherence services.
Leading CSOs have invested in market access consultancy and patient support divisions in recent years in order to meet the expected rise in demand for these services in this 10-year forecast period, and the increasing challenges and complexity of market access provides new opportunities for CSOs to provide services to meet these challenges."
Find data and information on this market in our new Pharma report Global Pharma Contract Sales Market 2019-2029: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services, Cardiovascular Disease, Metabolic Disorders, Oncology.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.